Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fate Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of B-cell lymphoma or CLL as described below:
B-Cell Lymphoma:
Histologically documented lymphomas expected to express CD19 and CD20
Relapsed/refractory disease following prior systemic immunochemotherapy regimen
Chronic Lymphocytic Leukemia (CLL):
Diagnosis of CLL per iwCLL guidelines
Relapsed/refractory disease following at least two prior systemic treatment regimens
ALL SUBJECTS:
Capable of giving signed informed consent
Age ≥ 18 years old
Stated willingness to comply with study procedures and duration
Contraceptive use for women and men as defined in the protocol
You may not be if
ALL SUBJECTS:
Females who are pregnant or breastfeeding
Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2
Body weight \<50 kg
Evidence of insufficient organ function
Receipt therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Day 1
Currently receiving or likely to require systemic immunosuppressive therapy
Prior allogeneic hematopoietic stem cell transplant (HSCT) or allogeneic CAR-T within 6 months of Day 1, or ongoing requirement for systemic GvHD therapy
Receipt of an allograft organ transplant
Known active central nervous system (CNS) involvement by malignancy
Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
Clinically significant cardiovascular disease
Known HIV infection
Known active Hepatitis B (HBV) or Hepatitis C (HCV) infection
Live vaccine \<6 weeks prior to start of lympho-conditioning
Known allergy to albumin (human) or DMSO
Clareo Health | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
